Tag Archives: Precision Medicine

Value Frameworks For Rare Diseases: Should They Be Different?

Despite increases in rare disease treatments attributable to the Orphan Drug Act, the economic value of rare disease treatments has come under increasing scrutiny. Assessing the value of treatments for rare diseases presents several unique challenges that should be considered by policymakers.

April 12, 2017

The Future Of Precision Medicine: Great Promise, Significant Challenges

Central to the PMI is the All of Us Research Program, which aims to enroll 1 million or more volunteers throughout the United States. If successful, it would be one of the largest longitudinal cohorts ever developed in this country.

February 28, 2017

Regulatory, Legal Uncertainties Are Barriers To Value-Based Agreements For Drugs

We conducted two-part double-blinded interviews with a group of five stakeholders regarding their experience with value-based agreements.

November 4, 2016

Worth The Money? Paying To Ensure A Representative Cohort In The Precision Medicine Initiative

By sequencing more genomes and linking genomic data to information in electronic health records and to participant-provided lifestyle data, the Precision Medicine Initiative will reveal to researchers and physicians the right treatments for the right patients.

July 30, 2015

Seven Big Ideas From Spotlight Health

A few of us from Health Affairs were lucky enough to attend Spotlight Health at the Aspen Ideas Festival in Aspen, Colorado. Here are just seven of the ideas that surprised us, impressed us, and even made us reexamine what we thought we already knew.

July 2, 2015